21.3 C
New York
Friday, June 5, 2026

Tag: presentation

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

Saputo Reports Financial Results for the Fourth Quarter and Fiscal 2026

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.

Saputo Reports Financial Results for the Fourth Quarter and Fiscal 2026

MONTREAL, June 04, 2026 (GLOBE NEWSWIRE) -- Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the fourth quarter and fiscal year ended on March 31, 2026. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS) Accounting Standards. The results of the Dairy Division (Argentina), which were previously reported under the International Sector, have been classified as discontinued operations, with comparative information presented accordingly, and with its assets and liabilities presented as held for sale.

Resideo Provides Update on Planned Spin-Off of ADI Global Distribution

Files Amended Form 10 Registration StatementAnnounces Scheduling Details for Resideo and ADI Investor DaysReaffirms Previously Announced Second Quarter and Full Year 2026 Outlook; Releases...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

X-energy Reports First Quarter 2026 Results

X-energy Reports First Quarter 2026 Results

Shoplazza Helps Australian Merchants Turn Product Ideas Into Ready-to-Sell Online Stores With AI

SYDNEY, June 4, 2026 /PRNewswire/ -- Shoplazza, a global AI-native eCommerce platform, is helping Australian merchants move faster from product idea to online store...

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

2026 ASCO LBA | Juncell Therapeutics’ GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

SHANGHAI, June 3, 2026 /PRNewswire/ -- On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPresentation